newsfilter
← Earnings
Earnings Releases·

MeiraGTx — Third Quarter 2026 Earnings Summary

  • Total revenue surged to $4.8 million from $0.4 million in the prior year period, driven by $1.6 million in new service revenue and $3.2 million in related-party services, while net loss narrowed slightly to $51.3 million from $50.5 million.
  • The company strengthened its balance sheet significantly, ending the quarter with $186.8 million in cash and cash equivalents compared to $17.1 million previously, alongside a shift from a shareholder equity deficit to $215.2 million in equity.
  • Strategic milestones include the completion of the MAA dossier for bota-vec (targeting EMA submission in December 2026), the initiation of a Phase 3 AAV-GAD study in Q1 2027, and a $75 million upfront payment received from Eli Lilly for AAV-AIPL1 rights.
  • Management projects sufficient capital to fund operations through the second half of 2028, with a commercial launch for bota-vec anticipated in late 2027 and a pivotal Phase 2 data readout for AAV2-hAQP1 expected in mid-2027.
Company
MEIRAGTX HOLDINGS PLC
Sector
Healthcare
Industry
Biotechnology